What type of study is this?

September 10, 2025JAMA

Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias

View Full Paper

Ask AI

Bookmark

The study reveals significant gaps in demographic data for AI devices aimed at Alzheimer's treatment and related dementias.
Only a limited range of demographic groups was represented in the data supporting FDA authorization of these devices.
Cohort analysis assessed the availability and quality of demographic data for AI and machine learning applications.
Highlights the need for more inclusive data to improve the effectiveness of AI devices for diverse populations.

Implication

Cohort study examines demographic data representativeness in FDA-authorized AI treatments for Alzheimer's, highlighting data gaps.

Abstract

This cohort study examines the availability and representativeness of data supporting US Food and Drug Administration–authorized artificial intelligence and machine learning devices to treat Alzheimer disease and related dementias.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68c19fa854b1d3bfb60db961 https://doi.org/10.1001/jama.2025.12779

View Full Paper

Ask AI

Bookmark

Implication

Cohort study examines demographic data representativeness in FDA-authorized AI treatments for Alzheimer's, highlighting data gaps.

Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias

Key Points

Implication

Abstract

Discussion

Cite This Study

Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading